Navigation Links
Generex Announces $3.0 Million Capital Investment
Date:1/25/2011

systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™ is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  Antigen Express has pioneered the use of specific CD4+ T helper stimulation in immunotherapy.  One of its platform technologies relies on inhibition of expression of the Ii protein.  Antigen Express scientists, and others, have shown clearly that suppression of expression of the Ii protein in cancer cells allows for potent stimulation of T helper cells and prevents the further growth of cancer cells.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-lo
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Additional Details for October 21st Live Video Webcast
2. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
3. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
4. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
5. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
6. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
7. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants
10. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
11. Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Once more, EMAAR has ... packaged waste water treatment plant to phase one of ... (KAEC). Two years ago Bioshaft successfully supplied and operated ... two residential towers with an occupancy of 900 residences. ... million gallons per day and was signed on September ...
(Date:12/17/2014)... AUSTIN, Texas , Dec. 16, 2014  Vermillion, ... company focused on gynecologic disease, today announced the next ... into a premier bio-analytics solutions provider with the naming ... to President and Chief Executive Officer, while current Chairman ... will continue to serve as Chairman. These changes are ...
(Date:12/15/2014)... December 15, 2014 METTLER TOLEDO ... PVM tool, ParticleView V19 with PVM technology ... probe-based particle vision and measurement tool continuously captures ... conditions. ParticleView V19 then automatically prepares a report ... particle size and concentration changes. This compelling blend ...
(Date:12/15/2014)... 15, 2014  Ascendis Pharma A/S, a biotechnology ... address significant unmet medical needs, today announced positive ... pediatric study to evaluate once-weekly TransCon Growth Hormone ... This interim analysis consists of 25 patients, representing ... the study, completing all six months of treatment. ...
Breaking Biology Technology:Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... p.m. PT ... (5:00 p.m. ET), IRVINE, Calif., ... CO-Oximetry and,Measure-Through-Motion- and-Low-Perfusion pulse oximetry, today announced,it will release third quarter financial ... Monday, October 27, 2008., A conference call to review the results ...
... Calif., Oct. 15 SuperGen, Inc.,(Nasdaq: SUPG ... and,development of novel cancer therapies, today announced the ... EORTC-NCI-AACR Symposium on "Molecular,Targets and Cancer Therapeutics" on ... will review clinical and non-clinical advances,in the following ...
... SourceSolution, a leader in,search technology for the biotechnology ... target to launch a new initiative next month,which ... manufacturing and,research organizations (CMOs/CROs). The proprietary technology will ... Service (SaaS) database. The,database will allow users to ...
Cached Biology Technology:Masimo to Report Third Quarter 2008 Financial Results on October 27, 2008 2SuperGen to Present Data at EORTC-NCI-AACR 2SourceSolution Announces the Launch of Its Initiative to Simplify Outsourcing Decisions for Biotechnology and Pharmaceutical Companies 2
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
(Date:11/18/2014)... 2014  The Secure Identity & Biometrics Association ... announce the formation of The Airport Entry and ... Identity and Biometric Entry and Exit Solutions Framework ... support from BORDERPOL, the international non-profit organization that ... expertise regarding border security, traveler and migration systems. ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... a serious environmental, economic and social problem worldwide as ... ecosystem functions, such as nutrient cycling. Despite substantial research, ... new habitats over native plants that technically should have ... is that these plants are more abundant in introduced ...
... Invasive plant species are a serious environmental, economic ... lost native biodiversity and ecosystem functions, such as nutrient ... about why some species dominate new habitats over native ... common but rarely tested assumption, say biologists, is that ...
... (Feb. 1, 2011) -- Rice University bioengineers and physician-scientists ... have successfully destroyed tumors of human brain cancer cells ... treatment that zaps glioma tumors with heat. The tests ... tumors with heat and avoid the unwanted side effects ...
Cached Biology News:Home and away: How do invasive plant species dominate native species? 2Home and away: Are invasive plant species really that special? 2Early tests find nanoshell therapy effective against brain cancer 2
...
... Kits are designed to speed up the PCR ... products, regardless of sequence or type of polymerase ... those that are difficult to clone by other ... or code for potentially detrimental proteins can be ...
... is the standard water based mounting medium ... the permanent preservation of peroxidase and alkaline ... to use and exhibits excellent optical characteristics. ... mounting medium that permits the long-term storage ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
Biology Products: